Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 2281 to 2290 of 2733 total matches.
Tizanidine for Spasticity
The Medical Letter on Drugs and Therapeutics • Jul 04, 1997 (Issue 1004)
and completely absorbed, especially in the presence of food. Plasma concentrations reach a peak in about 1 ...
Tizanidine (Zanaflex - Athena Neurosciences) has been approved by the US Food and Drug Administration for oral treatment of increased muscle tone associated with spasticity. It has been available in Europe and Japan for 12 years as a short-term muscle relaxant.
Bupropion (Zyban) for Smoking Cessation
The Medical Letter on Drugs and Therapeutics • Aug 15, 1997 (Issue 1007)
with doses up to 300 mg per day has been only about 0.1%. The incidence
might be higher in patients ...
Bupropion hydrochloride, currently available as an antidepressant (Wellbutrin - Medical Letter, 31:97, 1989; Wellbutrin SR), is now being marketed in a sustainedrelease formulation as Zyban (Glaxo Wellcome) for use as an aid in smoking cessation.
Tolcapone for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Jun 05, 1998 (Issue 1028)
decrease in "off" time of 1.4 hours (20%) with placebo, 2.3 hours (32%) with 100
mg t.i.d. of tolcapone ...
Tolcapone (Tasmar - Roche), a dihydroxy-methyl-nitrobenophenone, has been marketed as an adjunct to levodopa/carbidopa (Sinemet, and others) for treatment of Parkinson's disease in both stable patients and those with end-of-dose "wearing off"of levodopa.
Rituximab for Non-Hodgkins Lymphoma
The Medical Letter on Drugs and Therapeutics • Jun 19, 1998 (Issue 1029)
of 400 mg/hr. The cost to the pharmacist for 4
weekly infusions in a 1.7-m
2
patient is about $11,000 ...
Rituximab (Rituxan - IDEC Pharmaceutical/Genentech), a monoclonal antibody, has been approved by the FDA for treatment of low-grade B-cell non-Hodgkin's lymphoma. Most low-grade lymphomas are B-cell lymphomas.
Thalidomide
The Medical Letter on Drugs and Therapeutics • Oct 23, 1998 (Issue 1038)
inhibition of the synthesis of tumor
necrosis factor-α (JM Tramontana et al, Mol Med, 1:384, 1995). The drug ...
Thalidomide (Thalomid - Celgene), a synthetic derivative of glutamic acid, has been approved by the FDA for use in treatment of leprosy. Thalidomide was marketed in Europe in 1957 as a sedative but withdrawn four years later after being associated with severe human teratogenicity. The drug has since been found to be effective for several different indications.
Candesartan for Hypertension
The Medical Letter on Drugs and Therapeutics • Nov 20, 1998 (Issue 1040)
— Candesartan, like irbesartan, losartan and valsartan, blocks the
binding of angiotensin II to type 1 ...
Candesartan cilexetil (Atacand - Astra) is the fourth angiotensin II receptor antagonist to become available in the USA for oral treatment of hypertension.
Cevimeline (Evoxac) For Dry Mouth
The Medical Letter on Drugs and Therapeutics • Aug 07, 2000 (Issue 1084)
at 1000 Main Street, New Rochelle, NY
10801-7537. Subscription fees: 1 year, $49.00; 2 years, $82.00; 3 ...
Cevimeline hydrochloride, an acetylcholine derivative, has been approved by the FDA for treatment of dry mouth symptoms caused by Sjogren's syndrome. Presumably it could also be used to treat radiation-induced xerostomia in patients with head and neck cancer. Pilocarpine hydrochloride is FDA-approved for both indications
PC Spes
The Medical Letter on Drugs and Therapeutics • Feb 19, 2001 (Issue 1098)
at 1000 Main Street, New Rochelle, NY
10801-7537. Subscription fees: 1 year, $55.00; 2 years, $94.00; 3 ...
PC Spes, a dietary supplement sold for "prostate health", is being used increasingly to treat prostate cancer.
GlucoWatch Biographer: A Noninvasive Glucose Monitoring Device
The Medical Letter on Drugs and Therapeutics • May 14, 2001 (Issue 1104)
Rochelle, NY
10801-7537. Subscription fees: 1 year, $55.00; 2 years, $94.00; 3 years, $132.00 ($27.50—U.S ...
An automatic, noninvasive, glucose-monitoring device (GlucoWatch Biographer) has been approved for marketing by the FDA. The manufacturer states that it is not meant to replace a regular blood glucose meter.
Azelaic Acid (Finacea) for Rosacea
The Medical Letter on Drugs and Therapeutics • Sep 15, 2003 (Issue 1165)
with azelaic acid 15% gel applied twice daily and
from 17.6 to 10.5 and 18.5 to 12.1 with the vehicle alone ...
Azelaic acid 15% gel (Finacea Berlex) is now available in the US for treatment of mild to moderate rosacea. A 20% cream formulation of the drug (Azelex Allergan; Medical Letter 1996; 38:52) has been marketed here since 1996 for treatment of acne. The effectiveness of Finacea compared to its own vehicle and to metronidazole gel is discussed. Information on the drug's mechanism of action, adverse effects, dosage and cost are also included.
